Amicus Therapeutics – A Biopharmaceutical Firm Based in New Jersey

Amicus Therapeutics is a biopharmaceutical firm based in New Jersey, America. The firm went public in 2007 under the trading name, NASDAQ (Google Finance). The establishment of Amicus Therapeutics was financed by selected capital venture firms such as Radius Venture, New Enterprise Associates, and Canaan Partners. The organization focuses on the treatment of rare and orphan diseases, more so lysosomal storage disorders. The product development of the company is primarily based on CHART (Chaperone-Advanced Replacement Therapy), as well as enzyme replacement therapies.
In 2014, Amicus Therapeutics was noted as one of the companies that have the broadest portfolio of pharmacological chaperones small molecule in the pharmaceutical industry. Moreover, Amicus Therapeutics has a robust development pipeline for the treatment of various human genetic disease. For example, Amicus Therapeutics has a lead product known as migalastat. The product is a personalized medicine that is used for treating people with Fabry disease. Amicus Therapeutics is also working in collaboration with JCR Pharmaceutical and GlaxoSmithKline to explore coformulation with the recombinant alpha-galactosidase. However, the collaboration lasted for only three years.
Amicus does not have the manufacturing capability to produce its products. It relies on contracts from other companies for the manufacturing process. However, in 2008, the company expanded its operation. Apart from the normal research site in New Jersey, Amicus Therapeutics also has another research site in San Diego. Since its establishment, Amicus has been on the good side of the business. In 2010, Amicus Therapeutics received a grant worth $500000 from Michael Joseph Fox Foundation. The grant was meant to support the research study that was being conducted by Amicus in partnership with David Geffen Medical School. The company also received another grant worth $210300 from ADDF (Alzheimer’s Drug Discovery Foundation). Amicus Therapeutics used the grant to support its pre-clinical work. Also, in 2013, Amicus was able to have the necessary intellectual property and proprietary materials for the treatment of Pompe infection.

For more information visit: https://www.crunchbase.com/organization/amicus-therapeutics

| Twitter

 

Dick DeVos Continues To Search For Business Success

In 2004, the Grand Rapids, Michigan based business leader Dick DeVos shocked myself, and the majority of the business world by retiring from his position as the President of the AmWay group, which had by then become Alticor.

The Northwood University graduate had spent the majority of his business career working in the AmWay family and I feared he would decide to focus on his philanthropic work at this point in his career, however, I have been pleasantly surprised by the impact Dick and Betsy DeVos have made as investors for various companies looking for successful futures.

It is little wonder Dick DeVos has been such a major success after entering the business world in 1974 as a part of his father’s AmWay business; I have looked back at the career of Dick DeVos and discovered his career path has not been a simple one or been created with a simple path because of his family name. In fact, I was shocked to discover Dick had joined AmWay in 1974 with little fanfare and far below the executive level he did not reach until 1986.

At this point I was pleased to see the career of this well known education reformer had hit the heights as head of an international business division that played an important part for AmWay for the first time under his leadership. Read more: How and why the DeVos Family Gives Away Billions

It was only after proving himself an excellent businessperson outside AmWay that Dick DeVos, who now holds an estimated fortune of around $5 billion, was promoted to the position of President of AmWay after a short period in the same position with the Orlando Magic NBA franchise.

As the leader of AmWay I was pleased to see Dick did not stand still and simply continue on the same path carved out for the company by his father, Richard; instead, Dick and his brother, Doug, oversaw a major restructuring of the company to prepare it for the demands of the 21st century.

After retiring from AmWay in 2004 I worried Dick would not play a major role in business, but he has looked to develop The Windquest Group investment company in a bid to create new business opportunities. Dick DeVos has looked to develop investments in the areas that interest him in his current life, such as a number of businesses in the Michigan areas and clean energy choices.

Learn more about Dick DeVos: https://about.me/dick.devos